Article
Empagliflozin attenuates inflammation levels in autoimmune myocarditis through the STAT3 pathway and macrophage phenotype transformation.
Molecular immunology - 1 Mar 2024
Sheng Wenxin, Yu Jianshu, Zhang Hao, Zhang Jingbo
Abstract excerpt
OBJECTIVE: To investigate the anti-inflammatory actions and molecular mechanisms of the sodium/glucose cotransporter 2 (SGLT-2) inhibitor empagliflozin on autoimmune myocarditis. METHODS: The experimental autoimmune myocarditis (EAM) mouse model was constructed using peptides, and the therapeutic effects of empagliflozin on cardiac inflammation and fibrosis were observed using hematoxylin and eosin (HE), Sirius...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
